These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6782562)

  • 1. [Theophylline therapy in obstructive respiratory diseases. 2. Theophyllin-retard preparations for the long-term treatment of non-smokers with or without cardiac insufficiency (author's transl)].
    Wemhöner S; Oellerich M; Sybrecht G
    Prax Klin Pneumol; 1981 Jan; 35(1):42-6. PubMed ID: 6782562
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term therapy with a peroral effective theophyllin compound (author's transl)].
    Pertusini B; Zwick H
    Wien Med Wochenschr; 1980 Mar; 130(5):194-8. PubMed ID: 7395246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Theophylline therapy in obstructive respiratory diseases. 1. Bioavailability and pharmacokinetics of various theophylline preparations (author's transl)].
    Wemhöner S; Oellerich M; Sybrecht G
    Prax Klin Pneumol; 1981 Jan; 35(1):36-41. PubMed ID: 7208408
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of obstructive respiratory tract diseases. Study of afonilum retard in 3,512 patients].
    Eichhorn J; Perré R
    Med Welt; 1982 Dec; 33(50):1834-7. PubMed ID: 6762480
    [No Abstract]   [Full Text] [Related]  

  • 5. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
    Ranke C; Schmidt G; Oellerich M; Sybrecht GW
    Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of chronic obstructive respiratory syndrome with the new theophylline preparation Afonilum retard].
    Dettmer HH
    Fortschr Med; 1981 Jul; 99(25):1007-11. PubMed ID: 7262783
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long-term therapy with a retard theophylline preparation].
    Keller A; Bömches B; Kandt D
    Fortschr Med; 1995 May; 113(13):197-202. PubMed ID: 7782018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
    Pollert I
    Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
    [No Abstract]   [Full Text] [Related]  

  • 9. [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].
    Wiesner B; Sehrt I; Iwainsky H
    Z Erkr Atmungsorgane; 1984; 162(1):3-10. PubMed ID: 6719957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of theophylline-ethylenediamine in obstructive lung disease (author's transl)].
    Brossmann D; Ruf G; Wiessmann KJ
    Dtsch Med Wochenschr; 1980 Mar; 105(12):410-3. PubMed ID: 7363785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of obstructive respiratory disorders using a new theophylline retard preparation].
    Schroers M; Merbach W; Don M
    ZFA (Stuttgart); 1982 Jun; 58(17):974-8. PubMed ID: 7113392
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of sustained-release theophylline ('Theo-dur') for the treatment of chronic reversible obstructive lung disease in hospital practice.
    Riddington CJ; Shipman AJ
    Br J Clin Pract; 1985 Apr; 39(4):148-53. PubMed ID: 3893504
    [No Abstract]   [Full Text] [Related]  

  • 13. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
    Harder S; Staib AH; Stauder J
    Prax Klin Pneumol; 1985 Jun; 39(6):193-6. PubMed ID: 4022931
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined administration of controlled release theophylline and ranitidine: a 53-day controlled survey in patients with chronic obstructive lung disease (COLD) and peptic disease.
    Dal Negro R; Turco P; Pomari C; Trevisan F; De Conti F; Cordaro CI
    Br J Clin Pract; 1987 Nov; 41(11):1004-8. PubMed ID: 3504314
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical results obtained from a new controlled release theophylline preparation.
    Nolte D
    Br J Clin Pract Suppl; 1984; 32():14-7. PubMed ID: 6432017
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of obstructive respiratory tract diseases with pure theophylline retard].
    Arens PJ
    Med Klin Prax; 1982 Aug; 77(18):48-53, 67. PubMed ID: 6752679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical functional study of a new delayed-action preparation of "once a day" anhydrous theophylline in patients with chronic obstructive bronchopneumopathy].
    Gatto PG; Bruzzoni A; Valenti V
    Clin Ter; 1989 Jul; 130(1):45-9. PubMed ID: 2529079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological availability of two theophylline preparations (author's transl)].
    Kaik G
    Prax Klin Pneumol; 1982 Jun; 36(6):294-6. PubMed ID: 7111181
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative examination of theophylline-serum-concentrations and bronchospasmolytic effect of cholintheophyllinate (euspirax) and theophyllin-aethylendiamine (euphyllin retard) in patients with obstructive airway diseases (author's transl)].
    Wettengel R; Oellerich M; Schnitker J
    Prax Klin Pneumol; 1979 Nov; 33(11):1125-31. PubMed ID: 523424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Obstructive lung diseases. Efficient therapy using Phyllotemp retard].
    Vorberg G
    ZFA (Stuttgart); 1979 Feb; 55(6):397-9. PubMed ID: 419830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.